Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Yaqrit Prepares Phase 3 for Ammonia Scavenger in Hepatic Encephalopathy
Details : An ammonia scavenger, L-ornithine phenylacetate (OPA), is being evaluated for treatment of patients suffering from acute hepatic encephalopathy.
Product Name : Undisclosed
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 11, 2025
Lead Product(s) : Ornithine Phenylacetate
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EBX-102
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
EnteroBiotix Announces Positive Ph1b Clinical Results of EBX-102 in Liver Cirrhosis
Details : EBX-102 is a next-generation, full-spectrum drug candidate that contains highly diverse microbial ecosystems that restore and fortify the microbiome. It is being evaluated for Liver cirrhosis.
Product Name : EBX-102
Product Type : Microorganism
Upfront Cash : Inapplicable
November 11, 2024
Lead Product(s) : EBX-102
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : EBX-102
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : EBX-102 is an oral capsule that contains diverse full-spectrum microbial ecosystems that are intended to restore microbial ecology and act in concert to target multiple key disease pathways. It is being developed for in liver cirrhosis and hepatic enceph...
Product Name : EBX-102
Product Type : Microorganism
Upfront Cash : Inapplicable
March 28, 2023
Lead Product(s) : EBX-102
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Linerixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Study Phase : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Data showed that targeting bile acid reuptake with linerixibat, an ileal bile acid transporter (IBAT inhibitor), could provide relief for patients with cholestatic pruritus in PBC.
Product Name : GSK2330672
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 13, 2020
Lead Product(s) : Linerixibat
Therapeutic Area : Hepatology (Liver, Pancreatic, Gall Bladder)
Highest Development Status : Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable